Integrated Clinical and Network Pharmacology Study Reveals the Efficacy and Multi-Target Mechanism of Shenfu Injection in Septic Shock

This integrated clinical and network pharmacology study demonstrates that adjunctive Shenfu Injection significantly reduces 28-day mortality and accelerates recovery in septic shock patients, likely through a multi-target mechanism modulating inflammatory and cellular signaling pathways such as TNF, PI3K-Akt, and IL-17.

The Gist

Imagine your body is a bustling city. When a severe infection hits, it's like a massive riot breaking out. The city's emergency services (your immune system) go into overdrive, trying to fight the invaders. But in septic shock, the response gets out of control. The emergency services start burning down their own buildings, causing traffic jams, power outages, and chaos. This "cytokine storm" is what kills patients, not just the infection itself.

This paper is about testing a special "peacekeeping force" called Shenfu Injection (SFI) to see if it can calm the riot, save lives, and explain how it works.

Here is the story of the study, broken down simply:

1. The Big Experiment (The Clinical Trial)

The researchers gathered 80 patients in the hospital's emergency intensive care unit who were in the middle of this "riot" (septic shock). They split them into two groups:

• The Standard Group: Got the usual top-tier hospital care (antibiotics, fluids, machines to help breathing, and drugs to keep blood pressure up).
• The SFI Group: Got the same standard care, plus a daily dose of Shenfu Injection (a traditional Chinese medicine made from Red Ginseng and Aconite).

The Result:
The group that got the extra Shenfu Injection did significantly better.

• Survival: Only 20% of the SFI group died within 28 days, compared to 42.5% of the standard group. That's nearly half the death rate!
• Recovery: The SFI group's "riot" calmed down faster. Their inflammation markers dropped quicker, their blood cleared of waste products (lactate) faster, and they needed less help from blood-pressure drugs and ventilators. They got out of the ICU sooner.

2. The Detective Work (Network Pharmacology)

While the doctors were watching the patients get better, the scientists in the lab asked a big question: "How does this mixture of herbs actually fix such a complex problem?"

Traditional medicine is like a Swiss Army Knife—it has many tools (compounds) in one handle. Modern medicine often tries to find just one tool (one drug) to fix one problem. But septic shock is too messy for just one tool.

So, the researchers used a computer method called Network Pharmacology. Think of this as a giant social media map of the human body.

• They mapped out all the "users" (proteins and genes) involved in the septic shock riot.
• They mapped out all the "users" that the Shenfu Injection ingredients could talk to.
• They looked for the connections where the two maps overlapped.

What they found:
The Shenfu Injection didn't just hit one target; it hit 145 different targets simultaneously. It was like sending a peacekeeping force that could:

• Turn down the volume on the shouting (inflammation).
• Fix the power lines (cellular energy).
• Stop the buildings from collapsing (organ failure).

They found that key ingredients in the injection (like Ginsenoside Rh2 from Ginseng) acted like master keys, locking onto central hubs of the riot, such as a protein called IL-6 (a major alarm bell for inflammation).

3. The "Why" (The Mechanism)

The study suggests that Shenfu Injection works like a symphony conductor.

• Instead of silencing just one instrument (one chemical pathway), it conducts the whole orchestra.
• It tells the "inflammation" section to play softer.
• It tells the "cell survival" section to play louder.
• It helps the body's cells switch from "panic mode" back to "repair mode."

Because it works on so many levels at once, it manages to stabilize the patient in a way that single-target drugs often fail to do.

The Bottom Line

This study is a powerful combination of real-world proof and computer detective work.

• Real World: Adding Shenfu Injection to standard care saved lives and helped patients recover faster.
• Computer Proof: It showed that the medicine works by gently guiding the body's complex defense systems back to balance, rather than just blasting one specific target.

In short: When the body's city is under siege, Shenfu Injection acts like a highly skilled mediator that calms the chaos, repairs the damage, and helps the city get back to normal, all while the standard medical team handles the immediate fires.

Technical Summary

1. Problem Statement

Septic shock remains a critical global health challenge with high mortality rates despite advances in standard care (antimicrobials, fluid resuscitation, and vasopressors). The pathophysiology involves a dysregulated host response leading to a "cytokine storm," endothelial damage, and metabolic crisis.

• Clinical Gap: While Traditional Chinese Medicine (TCM), specifically Shenfu Injection (SFI), has shown promise in stabilizing hemodynamics and improving outcomes in China, its precise molecular mechanisms remain unclear ("black box").
• Scientific Gap: Conventional single-target research paradigms are insufficient to explain the efficacy of multi-component herbal medicines. There is a need for an integrative approach that combines rigorous clinical evidence with systems biology to elucidate the multi-target mechanisms of SFI.

2. Methodology

The study employed a dual-strategy approach: a prospective randomized clinical trial and a computational network pharmacology analysis.

A. Clinical Study (Randomized Controlled Trial)

• Design: Open-label, randomized, controlled trial conducted at a single center (Hebei Cangzhou Integrated Traditional Chinese and Western Medicine Hospital) from Jan 2023 to Jan 2025.
• Participants: 80 patients diagnosed with septic shock (Sepsis-3 criteria) and TCM "Yangqi Baotuo" syndrome.
  • Inclusion: Age 18–65, SOFA score increase ≥2, MAP <65 mmHg requiring vasopressors, lactate >2 mmol/L.
  • Exclusion: Terminal malignancy, acute cardiovascular events, severe organ failure, pregnancy, or allergy to SFI.
• Intervention:
  • Control Group: Standard of care (antimicrobials, fluids, vasopressors, organ support).
  • SFI Group: Standard care + 60 mL Shenfu Injection diluted in 250 mL 5% glucose, IV once daily for 7 days.
• Outcomes:
  • Primary: 28-day all-cause mortality.
  • Secondary: Inflammatory markers (PCT, CRP, IL-6), oxygen metabolism (lactate clearance, ScvO₂, PaO₂/FiO₂), hemodynamic stability (vasopressor duration, time to MAP target), organ function (SOFA, APACHE II scores), and safety.
• Analysis: Intention-to-treat principle; logistic regression for mortality risk factors.

B. Network Pharmacology & Molecular Docking

• Component Screening: Active components from Panax ginseng and Aconitum carmichaelii were screened using TCMSP (criteria: OB ≥30%, DL ≥0.18).
• Target Prediction:
  • Drug targets predicted via SwissTargetPrediction.
  • Disease targets (septic shock) retrieved from GeneCards.
  • Intersection identified 145 common therapeutic targets.
• Network Construction:
  • PPI Network: Built using STRING (confidence >0.4) and visualized in Cytoscape to identify hub targets (high betweenness centrality).
  • Enrichment Analysis: GO (Biological Process, Cellular Component, Molecular Function) and KEGG pathway analysis via DAVID.
  • Validation: Molecular docking (AutoDock Vina) verified binding affinities between top active components and core targets.

3. Key Contributions

1. Integrated Evidence: First study to concurrently validate the clinical efficacy of SFI in septic shock while simultaneously mapping its multi-target molecular mechanism using network pharmacology.
2. Mechanistic Elucidation: Moves beyond the "black box" of TCM by identifying specific bioactive compounds (e.g., Ginsenoside Rh2, Deltoin) and their interaction with critical signaling hubs (IL-6, SRC, MAPK3).
3. Clinical Validation: Provides robust data from a randomized trial showing significant mortality reduction and accelerated recovery in a high-risk population.

4. Key Results

Clinical Outcomes

• Mortality: The 28-day all-cause mortality was significantly lower in the SFI group (20.0%) compared to the control group (42.5%, P = 0.030).
• Inflammation & Metabolism:
  • SFI group showed faster and greater reductions in IL-6, PCT, and CRP (Day 7: P < 0.001).
  • Lactate clearance at 6 hours was significantly higher in the SFI group (35.2% vs. 18.5%, P < 0.001).
  • Improved oxygenation (PaO₂/FiO₂) and tissue perfusion (ScvO₂).
• Clinical Recovery:
  • Shorter vasopressor duration (48h vs. 72h, P < 0.001).
  • Shorter mechanical ventilation (96h vs. 144h, P = 0.002).
  • Reduced ICU length of stay (7.0 vs. 10.0 days, P = 0.003).
  • Greater improvement in SOFA and APACHE II scores.
• Safety: No significant difference in adverse events between groups; no serious SFI-related adverse events reported.

Network Pharmacology Findings

• Active Components: Identified 25 components (4 from Ginseng, 21 from Aconite). Key compounds included Ginsenoside Rh2, Deltoin, DNOP, and Karanjin.
• Core Targets: 145 common targets were identified. The PPI network highlighted IL-6, SRC, PPARG, MAPK3, and HSP90AA1 as central hubs.
• Pathway Enrichment: Significant enrichment in:
  • TNF signaling pathway
  • PI3K-Akt signaling pathway
  • IL-17 signaling pathway
  • AGE-RAGE signaling pathway (oxidative stress/endothelial dysfunction).
• Molecular Docking: Confirmed strong binding affinities (low binding energy) between key components (e.g., Ginsenoside Rh2) and core targets (e.g., IL-6, MAPK3).

5. Significance

• Therapeutic Implication: The study provides high-level evidence supporting SFI as a valuable adjunctive therapy for septic shock, capable of reducing mortality and shortening ICU stays.
• Mechanistic Insight: The findings suggest SFI operates via a "multi-component, multi-target" strategy. It likely dampens the cytokine storm (via IL-6/TNF/IL-17 inhibition) while simultaneously promoting cell survival and metabolic recovery (via PI3K-Akt and SRC modulation). This holistic approach may explain why SFI succeeds where single-target biologics have often failed in sepsis trials.
• Paradigm Shift: This study exemplifies a modern paradigm for TCM research, bridging clinical outcomes with systems biology to provide a theoretical framework for the rational use of complex natural products in critical care.
• Future Directions: The authors acknowledge limitations (single-center, open-label) and call for multi-center, double-blind trials and further in vivo validation of the predicted molecular pathways.